Cogent Biosciences, Inc.

NASDAQ•COGT

執行長: Mr. Andrew R. Robbins M.B.A.

板塊: Healthcare

行業: Biotechnology

上市日期: 2018-03-29

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

聯絡資訊

275 Wyman Street, 3rd Floor, Waltham, MA, 02451, United States

617-945-5576

www.cogentbio.com

市值

$6.01B

本益比 (TTM)

-7.6

19.7

股息率

52周最高

$43.73

52周最低

$3.72

52周範圍

83%

排名47Top 61.9%

3.4

F-Score

改良版 Piotroski 分析

基於 10 年期基本面

疲弱 • 3.4 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2016-2025

財務儀表板

Q4 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.69+0.00%

近4季度走勢

自由現金流

-$79.92M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Bezuclastinib Clinical Progress Positive top-line results achieved for SM and GIST indications in 2025; NDA submission for NonAdvSM completed.

Financing Activities Strong Financing provided $878.2M in 2025, including $222.8M from Notes issuance, bolstering capital resources.

Cash Position Strong Cash, equivalents, and securities totaled $900.8M as of December 31, 2025, funding operations into 2028.

R&D Spending Increased Research and development expenses rose $37.1M to $269.78M in 2025, supporting clinical trial progression.

關注風險

Continued Net Losses Incurred Net loss reached $328.94M in 2025, increasing $73.08M from 2024; operations remain unprofitable.

Pipeline Dependency Risk Business success highly dependent on bezuclastinib program success; pipeline expansion requires substantial funding.

Manufacturing Sole Source Risk API and drug product for bezuclastinib rely on single-source suppliers; loss significantly harms business operations.

Regulatory Approval Uncertainty Regulatory plans may face disagreement from FDA; approval for all indications is not guaranteed.

未來展望

Commercial Launch Planned Expect US commercial launch for NonAdvSM in second half of 2026, pending successful FDA regulatory approval.

Pipeline Advancement Continues Plan to initiate Phase 1 study for ErbB2 inhibitor and submit IND for KRAS/JAK2 programs in 2026.

Future Capital Requirements Expect substantial future expenses; additional financing required to complete development and commercialization efforts.

GIST NDA Submission Target Expect to complete GIST NDA submission in April 2026, following RTOR acceptance in January 2026.

同行對比

營業收入 (TTM)

SRPT

$2.20B

+15.6%

GLPG

$1.26B

+303.5%

RCUS

$247.00M

-4.3%

毛利率 (最新季度)

AGIO

96.9%

-4.3pp

LQDA

94.2%

+29.3pp

RCUS

90.9%

-7.7pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
IBRX	$9.25B	-25.3	64.3%	175.0%
COGT	$6.01B	-7.6	-100.2%	27.0%
DNLI	$3.18B	-7.0	-50.1%	3.7%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月4日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料